Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis

By sjmartinez • December 21, 2023

Blauvelt A, Rich P, Sofen H, Strober B, Merola JF, Lebwohl M, Morita A, Szepietowski JC, Lambert J, Hippeli L, Colston E, Balagula E, Banerjee S, Thaçi D. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis. J Am Acad Dermatol. 2023 Dec 18:S0190-9622(23)03374-1. doi: 10.1016/j.jaad.2023.11.060. Epub ahead of print. PMID: 38122848.

Tags: apremilast, Clinical Trial, Dermatology, deucravacitinib, Olive View DoM, psoriasis, Publications, scalp psoriasis, TYK2, tyrosine kinase 2

Assessing GPT-4’s Diagnostic Accuracy with Darker Skin Tones: Underperformance and Implications

Akuffo-Addo E, Samman L, Munawar L, Akbik M, Kokikian N, Wescott R, Wu JJ. Assessing GPT-4's Diagnostic Accuracy with Darker Skin Tones: Underperformance and Implications.[...]

Engaging industry effectively and ethically in artificial intelligence from the Augmented Artificial Intelligence Committee Standards Workgroup

Lee I, Aninos A, Lester J, Rotemberg V, Schlessinger DI, Weed J, Wongvibulsin S, Daneshjou R. Engaging industry effectively and ethically in artificial intelligence from[...]

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers

Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford[...]